215 related articles for article (PubMed ID: 10910310)
1. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
Kaplan-Machlis B; Spiegler GE; Zodet MW; Revicki DA
Arch Fam Med; 2000 Jul; 9(7):624-30. PubMed ID: 10910310
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease.
Revicki DA; Sorensen S; Maton PN; Orlando RC
Dig Dis; 1998; 16(5):284-91. PubMed ID: 9892788
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial.
Maton PN; Orlando R; Joelsson B
Aliment Pharmacol Ther; 1999 Jun; 13(6):819-26. PubMed ID: 10383513
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
6. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Revicki DA; Crawley JA; Zodet MW; Levine DS; Joelsson BO
Aliment Pharmacol Ther; 1999 Dec; 13(12):1621-30. PubMed ID: 10594397
[TBL] [Abstract][Full Text] [Related]
7. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease.
Hillman AL; Bloom BS; Fendrick AM; Schwartz JS
Arch Intern Med; 1992 Jul; 152(7):1467-72. PubMed ID: 1627026
[TBL] [Abstract][Full Text] [Related]
8. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
[TBL] [Abstract][Full Text] [Related]
10. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
11. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Festen HP; Schenk E; Tan G; Snel P; Nelis F
Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
[TBL] [Abstract][Full Text] [Related]
14. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
15. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
[TBL] [Abstract][Full Text] [Related]
16. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.
Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir DG; Gillon KR; Peacock RA; Fulton C
BMJ; 1999 Feb; 318(7182):502-7. PubMed ID: 10024259
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.
Revicki DA; Zodet MW; Joshua-Gotlib S; Levine D; Crawley JA
Health Qual Life Outcomes; 2003 Nov; 1():73. PubMed ID: 14641914
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study.
Rush DR; Stelmach WJ; Young TL; Kirchdoerfer LJ; Scott-Lennox J; Holverson HE; Sabesin SM; Nicholas TA
J Fam Pract; 1995 Aug; 41(2):126-36. PubMed ID: 7636452
[TBL] [Abstract][Full Text] [Related]
20. Combination drug therapy for gastroesophageal reflux disease.
Cross LB; Justice LN
Ann Pharmacother; 2002 May; 36(5):912-6. PubMed ID: 11978171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
